Cascadian Therapeutics (FRA:3O61) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of Jun. 06, 2024)

View and export this data going back to . Start your Free Trial

What is Cascadian Therapeutics EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Cascadian Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Cascadian Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Cascadian Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cascadian Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cascadian Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Cascadian Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Cascadian Therapeutics (FRA:3O61) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Cascadian Therapeutics EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Cascadian Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cascadian Therapeutics (FRA:3O61) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cascadian Therapeutics Inc (FRA:3O61) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cascadianrx.com

Cascadian Therapeutics Inc is a clinical-stage biopharmaceutical company focusing in developing innovative therapeutic product candidates for the treatment of cancer. Its objective is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. The company's clinical-stage product candidate includes ONT-380, an orally active and selective small molecule HER2 inhibitor. In addition, it is also engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 kinase inhibitor and protocell technology. All the business activity of the firm is functioned through the region of United States.

Cascadian Therapeutics (FRA:3O61) Headlines

No Headlines